Last reviewed · How we verify
NCT05706116
Controlled Human Infection Study of Orally Administered Trichuris Trichiura Eggs in Naïve Adults
Phase 1 trial testing Trichuris trichiura Egg Inoculum in Whipworm in 18 participants. Currently enrolling.
23 October 2027
Quick facts
| Lead sponsor | George Washington University |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 10 September 2025 |
| Primary completion | 23 October 2027 |
| Estimated completion | 30 April 2028 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Trichuris trichiura Egg Inoculum — full drug profile →
Conditions studied
- Whipworm — all drugs for Whipworm →
- Trichuriasis — all drugs for Trichuriasis →
- Controlled Human Infection — all drugs for Controlled Human Infection →
Sponsor
George Washington University
Who can join
Adults 18 to 45, any sex, with Whipworm or Trichuriasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Controlled Human Infection Model (CHIM) is being developed to provide early proof-of-concept that experimental infection with the intestinal nematode, Trichuris trichiura, is feasible and safe. The proposed model consists of enrolling consenting, healthy, trichuriasis-naïve adults and challenging them with the investigational product, Trichuris trichiura Egg Inoculum, to assess their ability to result in detectable infection. The proposed study will be a feasibility study that will consist of administering different doses of the Trichuris trichiura Egg Inoculum to healthy adult volunteers to determine the optimal dose (i.e., number of T. trichiura eggs) that is safe, well-tolerated and results in consistent infection.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Advances in vaccine development through the controlled human infection models for hookworm and schistosomiasis.
Hoogerwerf MA, Egesa M, Agnandji ST, Loukas A, et al · · 2026 · PMID 41926449 · DOI 10.1371/journal.pntd.0014137
Verify or expand the search:
- PubMed search for NCT05706116
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other George Washington University trials
Trials by the same sponsor.
- NCT07279129 — Decision Support Tool to Integrate PrEP Into Emergency Departments · Phase 1 · not yet recruiting
- NCT07524309 — Self-Help Plus Pilot Study, Colombia: Train2Care · NA · not yet recruiting
- NCT07249008 — NSS Grocery Store Brazil · NA · recruiting
- NCT07000513 — HIV Self-Testing and Long-Acting Injectables for HIV Treatment and Prevention Among Commercial Minibus Drivers (I-TEST L · Phase 4 · not yet recruiting
- NCT07079306 — ChatGPT-Supported Text Messaging Program for Smoking Cessation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05706116 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by George Washington University
- Last refreshed: 4 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05706116.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing